How Enzyme Replacement Therapy Treats Hypophosphatasia: Vital Steps

Hypophosphatasia (HPP) is a rare, inherited metabolic bone disorder caused by deficient activity of the enzyme tissue-nonspecific alkaline phosphatase (TNSALP). Without enough TNSALP, key mineral substrates build up, preventing normal bone and tooth mineralization. Until recently, care focused on symptom relief. Today, enzyme replacement therapy (ERT) with asfotase alfa offers a targeted hypophosphatasia treatment that addresses the underlying enzyme deficiency. Below are the vital steps in how ERT works and what patients and caregivers should know.

1. Understanding Hypophosphatasia

• Genetic cause
  HPP arises from mutations in the ALPL gene, which encodes TNSALP. Severity ranges from lethal perinatal forms to mild adult or dental-only forms.
• Pathophysiology
  Low TNSALP activity leads to accumulation of substrates such as inorganic pyrophosphate (PPi), pyridoxal 5′-phosphate (PLP) and phosphoethanolamine (PEA). Excess PPi inhibits hydroxyapatite crystal formation, causing under-mineralized bones and teeth.
• Clinical features
  Symptoms vary by age at onset, but commonly include:
  • Bone pain and fractures
  • Rickets-like deformities in infants and children
  • Muscle weakness and gait disturbances
  • Premature tooth loss
  • Respiratory complications in severe cases

2. Rationale for Enzyme Replacement Therapy

Conventional management (orthopedic surgery, pain control, respiratory support) does not correct the enzyme deficiency. ERT with asfotase alfa—a recombinant, bone-targeted TNSALP—replaces the missing enzyme, allowing normal mineralization to resume.

How Asfotase Alfa Works

• TNSALP replacement
  Delivers functional enzyme directly to bone surfaces.
• Bone targeting
  Engineered with a deca-aspartate motif that binds hydroxyapatite, concentrating enzyme activity where mineralization occurs.
• Substrate clearance
  Restores breakdown of PPi and PLP, reducing inhibitors of mineralization and normalizing vitamin B6 metabolism.

3. Identifying Candidates for ERT

Proper diagnosis and patient selection are critical:

• Biochemical testing
  Low serum alkaline phosphatase, elevated PPi and PLP levels.
• Genetic confirmation
  ALPL gene mutation analysis to confirm HPP subtype.
• Clinical assessment
  Severity of bone disease, fracture history, growth parameters (children) and functional status.
• Imaging
  X-rays, DXA scans and in some cases MRI to assess bone density and deformities.

Patients with moderate to severe childhood-onset HPP and perinatal-lethal forms are prime ERT candidates. Adults with painful fractures or poor bone healing may also benefit.

4. Initiating Treatment

Once diagnosis and eligibility are confirmed, a multidisciplinary team should coordinate care:

• Dose selection
  Pediatric dose: typically 2 mg/kg three times per week (subcutaneous).
  Adult dose: evaluated case-by-case, often similar per-kg dosing.
• Administration training
  Teach patients or caregivers subcutaneous injection technique, site rotation and syringe storage.
• Baseline monitoring
  Labs: serum alkaline phosphatase, calcium, phosphate, vitamin D.
  Imaging: establish baseline bone status.
  Functional tests: 6-minute walk, motor development scales (children).

5. Monitoring Response and Safety

Consistent follow-up ensures optimal outcomes:

• Laboratory monitoring
  Check serum alkaline phosphatase monthly until stable, then every 3–6 months. Monitor calcium and phosphate to detect shifts in mineral metabolism.
• Radiographic evaluation
  Repeat X-rays every 6–12 months to assess healing of rickets, fracture repair and deformity improvement.
• Functional assessments
  Track growth in children, mobility scores, pain scales and quality-of-life questionnaires.
• Antibody testing
  Although rare, anti-asfotase alfa antibodies can develop. If there’s unexplained loss of response, test for neutralizing antibodies.

6. Managing Side Effects

Most patients tolerate ERT well. Common, generally mild side effects include:

• Injection-site reactions (redness, itching, discomfort)
• Transient fever or flu-like symptoms after injections
• Hypocalcemia, especially during early treatment as mineralization “pulls” calcium into bone

Management strategies:

• Rotate injection sites and use proper technique.
• Pre-medicate with acetaminophen for fever or discomfort if needed.
• Maintain adequate dietary calcium and vitamin D; adjust supplements under medical supervision.
• Supplement with vitamin B6 if neurological symptoms emerge from PLP shifts.

7. Supporting Long-Term Care

Hypophosphatasia is a lifelong condition. A comprehensive care plan should include:

• Multidisciplinary team
  Endocrinologist or metabolic specialist, orthopedic surgeon, dentist, physical therapist, nutritionist.
• Dental monitoring
  Tooth development and gingival health must be tracked to prevent premature loss.
• Physical therapy
  Tailored programs to build strength, improve gait and prevent contractures.
• Nutrition counseling
  Balanced intake of calcium, phosphate and vitamin D—avoiding extremes that could worsen mineral imbalance.
• Psychosocial support
  Chronic disease can impact mental health. Counseling or support groups may help patients and families cope.

8. Measuring Success

Key indicators that ERT is effective:

• Radiographic evidence of healing rickets and improved bone density
• Reduced fracture rate and decreased need for orthopedic surgery
• Increased mobility, strength and endurance
• Improved growth curves in children
• Better dental outcomes with fewer lost teeth

9. Considering a Symptom Check

Early symptom recognition speeds diagnosis and treatment. If you or a family member experience unexplained bone pain, fractures, delayed motor milestones or premature tooth loss, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Free, Online Symptom Check: doctor approved Ubie Symptom Checker

10. When to Speak to a Doctor

While enzyme replacement therapy has transformed hypophosphatasia treatment, it’s not a substitute for professional medical evaluation. Always speak to a doctor if you experience:

• Severe bone pain or new fractures
• Difficulties breathing or swallowing
• Signs of low calcium (numbness, muscle cramps)
• Any serious or life-threatening change in health

Early intervention and ongoing collaboration with healthcare providers maximize the benefits of ERT and help maintain bone health, function and quality of life.